Page last updated: 2024-12-06

cyclam

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cyclam (1,4,8,11-tetraazacyclotetradecane) is a macrocyclic ligand known for its ability to bind to metal ions, particularly transition metals. Its synthesis involves the condensation of 1,2-dibromoethane with ethylenediamine, followed by ring closure. Cyclam exhibits a high affinity for various metal ions, forming stable complexes with a variety of applications. Its strong coordination properties make it a valuable tool in fields such as medicine, catalysis, and materials science. Cyclam derivatives are studied for their potential in therapeutic applications, such as drug delivery, diagnostic imaging, and the treatment of diseases like cancer and Alzheimer’s. Research is ongoing to explore the diverse applications of cyclam and its derivatives.'

cyclam: RN given refers to parent cpd; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID64964
CHEMBL ID125150
CHEBI ID37401
SCHEMBL ID33477
MeSH IDM0082927

Synonyms (51)

Synonym
nsc180811
nsc-180811
1,8,11-tetraazacyclotetradecane
295-37-4
MLS000069469
smr000059059
1,4,8,11-tetraazacyclo-tetradecane
CHEBI:37401 ,
[14]anen4
CBDIVE_013909
ips2
jm1498
1,4,8,11-tetraazacyclotetradecane
cyclam
1,4,8,11-tetrazacyclotetradecane
1,4,8,11-tetraazacyclotetradecane, 98% (gc)
jm 1498
nsc 180811
einecs 206-039-1
brn 0111811
NCGC00018136-01
1,4,8,11tetraaza-cyclotetradecane
CHEMBL125150
T1597
NCGC00018136-02
NCGC00018136-03
A819951
ep5az544vp ,
5-26-11-00027 (beilstein handbook reference)
unii-ep5az544vp
FT-0624146
AM84902
AKOS015854525
STL333618
1,4,8,11-tetra-aza cyclotetradecane
SCHEMBL33477
Q-200078
CS-W019774
cyclam(1,4,8,11-tetraazacyclotetradecane)
c10h24n4
mfcd00005105
DTXSID30183698
SY010380
BCP05842
1,4,8,11-tetraaza-cyclotetradecane
AS-19218
Q1970333
jm-1498
14-crown-4n4
EN300-202126
Z1269214154

Research Excerpts

Overview

summarize : . Cu cyclam is a useful platform to make excellent HNO sensors including imaging agents.

ExcerptReferenceRelevance
"Cu cyclam is a useful platform to make excellent HNO sensors including imaging agents."( Mechanistic Origin of Favorable Substituent Effects in Excellent Cu Cyclam Based HNO Sensors.
Chu, JM; Shi, Y; Stella, G; Zhang, Y, 2022
)
1.47

Dosage Studied

ExcerptRelevanceReference
" T1 measurements by pulsed MR imaging and manganese analyses on excised tissue showed that both relaxation rate (1/T1) and manganese content of liver and kidney increase linearly with the dosage of Mn(cyclam)."( Paramagnetic macrocyclic complexes as contrast agents for MR imaging: proton nuclear relaxation rate enhancement in aqueous solution and in rat tissues.
Hinson, WH; Jackels, SC; Karstaedt, N; Kroos, BR; Moran, PR, 1986
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
saturated organic heteromonocyclic parent
crown amineCrown compounds containing only nitrogen as coordinating atom.
azacycloalkane
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
survival motor neuron protein isoform dHomo sapiens (human)Potency1.12200.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID105151Concentration required to protect the virus infected cells against viral cytopathicity was measured on HIV-1(IIIB) virus strain in MT-4 cells1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.
AID1239032Cytotoxicity against human HCT116 cells incubated for 24 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Antiproliferative and apoptosis-inducing activities of novel naphthalimide-cyclam conjugates through dual topoisomerase (topo) I/II inhibition.
AID317100Inhibition of mouse neuroblast cell migration from subventricular zone tissue explants at 250 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Discovery of new small molecules that influence neuroblast cell migration from the subventricular zone.
AID104778Concentration required to reduce the viability of mock-infected MT-4 cells1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.
AID105152Concentration required to protect the virus infected cells against viral cytopathicity was measured on HIV-2(ROD) virus strain in MT-4 cells1995Journal of medicinal chemistry, Jan-20, Volume: 38, Issue:2
Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-tetraazamacrocycles that inhibit HIV replication. Effects of macrocyclic ring size and substituents on the aromatic linker.
AID1239031Cytotoxicity against human HeLa cells incubated for 24 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Antiproliferative and apoptosis-inducing activities of novel naphthalimide-cyclam conjugates through dual topoisomerase (topo) I/II inhibition.
AID317101Inhibition of mouse neuroblast cell migration from subventricular zone tissue explants at 25 uM after 48 hrs relative to control2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Discovery of new small molecules that influence neuroblast cell migration from the subventricular zone.
AID1239030Cytotoxicity against human A549 cells incubated for 24 hrs by sulforhodamine B assay2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Antiproliferative and apoptosis-inducing activities of novel naphthalimide-cyclam conjugates through dual topoisomerase (topo) I/II inhibition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (164)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (3.66)18.7374
1990's8 (4.88)18.2507
2000's61 (37.20)29.6817
2010's80 (48.78)24.3611
2020's9 (5.49)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.30

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.30 (24.57)
Research Supply Index5.11 (2.92)
Research Growth Index5.32 (4.65)
Search Engine Demand Index168.36 (26.88)
Search Engine Supply Index4.00 (0.95)

This Compound (52.30)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (3.05%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other159 (96.95%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]